All Studies Meta Analysis Recent:

Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study

Alam et al., Cureus, doi:10.7759/cureus.14933

May 2021

Post
Facebook

Source PDF All Meta

Bamlanivimab/etesevimab

20th treatment shown to reduce risk in May 2021

^*, now known with p = 0.00029 from 20 studies, recognized in 4 countries. Efficacy is variant dependent.

Lower risk for mortality, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,100+ studies for 60+ treatments. c19early.org

Retrospective 246 nursing home patients showing lower mortality with early bamlanivimab treatment.

Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron Haars, Liu, Pochtovyi, Sheward, VanBlargan.

1. Haars et al., Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023, Microorganisms, doi:10.3390/microorganisms11102417.mdpi.com, doi.org.

2. Liu et al., Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2, bioRxiv, doi:10.1101/2021.12.14.472719.biorxiv.org, doi.org.

3. Pochtovyi et al., In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, Vaccines, doi:10.3390/vaccines11101533.mdpi.com, doi.org.

4. Sheward et al., Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron), bioRxiv, doi:10.1101/2021.12.19.473354.biorxiv.org, doi.org.

5. VanBlargan et al., An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies, bioRxiv, doi:10.1101/2021.12.15.472828.biorxiv.org, doi.org.

Important missing comments or errors? Let us know.

risk of death, 75.0% lower, OR 0.25, p = 0.03, treatment 160, control 86, RR approximated with OR.

risk of hospitalization, 65.0% lower, OR 0.35, p = 0.08, treatment 160, control 86, RR approximated with OR.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Alam et al., 10 May 2021, retrospective, USA, peer-reviewed, mean age 82.4, 9 authors, study period 15 November, 2020 - 31 January, 2021. Contact: dr.tuku@yahoo.com.

This Paper Bamlaniv../e..All

Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study

Mohammud M Alam, Saborny Mahmud, Sandeep Aggarwal, Sawsan Fathma, Naim Al Mahi, Mohammed S Shibli, Siddiqi M Haque, Sharothy Mahmud, Ziauddin Ahmed

Cureus, doi:10.7759/cureus.14933

Importance Coronavirus disease 2019 (COVID-19) outbreaks are frequent occurrences in nursing homes and long-term care facilities (LTCFs), resulting in subsequent hospitalization and death. Rationale Virus-neutralizing monoclonal antibodies demonstrate a significant decrease in both viral load and hospital transfer rate among patients with mild-to-moderate COVID-19 infection. Objective To assess the clinical outcomes of COVID-19 patients with mild-to-moderate symptoms in LTCFs who received LY-CoV555 as compared to those who did not receive this treatment. Design Retrospective case-control study and logistic regression analysis. Setting LTCFs in New York. Participants Two-hundred forty-six (246) LTCF patients diagnosed with mild-to-moderate COVID-19 infection with positive COVID-19 polymerase chain reaction (PCR) from November 15, 2020, to January 31, 2021. Methods Two-hundred forty-six (246) COVID-19 patients were identified from electronic medical records, out of which 160 cases were exposed to LY-CoV555 treatment (700 mg single dose, intravenous infusion). Eightysix (86) patients were unexposed controls who did not receive monoclonal antibodies, LY-CoV555. Outcome We assessed the odds of death and hospitalization of exposed cases as compared to unexposed controls. Using logistic regression analysis, we also assessed the risk factors associated with these outcomes in the entire sample population.

Additional Information Disclosures Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

Ahmad, Alam, Saadi, Doxycycline and hydroxychloroquine as treatment for high-risk COVID-19 patients: experience from case series of 54 patients in long-term care facilities, MedRxiv, doi:10.1101/2020.05.18.20066902?utm_medium=email&utm_source=transaction

Ahmed, Karim, Ross, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.191?utm_medium=email&utm_source=transaction

Alam, Mahmud, Rahman, Simpson, Aggarwal et al., Clinical outcomes of early treatment with doxycycline for 89 high-risk COVID-19 patients in long-term care facilities in New York, Cureus, doi:10.7759/cureus.9658?utm_medium=email&utm_source=transaction

Anderson, Rouphael, Widge, Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults, N Engl J Med, doi:10.1056/NEJMoa2028436?utm_medium=email&utm_source=transaction

Borba, Val, Sampaio, Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.8857?utm_medium=email&utm_source=transaction

Chen, Nirula, Heller, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2029849?utm_medium=email&utm_source=transaction

Conti, Ronconi, Caraffa, Gallenga, Ross et al., Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COV-19 or SARS-CoV-2): antiinflammatory strategies, J Biol Regul Homeost Agents, doi:10.23812/CONTI-E?utm_medium=email&utm_source=transaction

Dagan, Barda, Kepten, BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting, N Engl J Med, doi:10.1056/NEJMoa2101765?utm_medium=email&utm_source=transaction

Duan, Liu, Li, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2004168117?utm_medium=email&utm_source=transaction

Fauci, Lane, Redfield, Covid-19 -navigating the uncharted, N Engl J Med, doi:10.1056/NEJMe2002387?utm_medium=email&utm_source=transaction

Hansen, Baum, Pascal, Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail, Science, doi:10.1126/science.abd0827?utm_medium=email&utm_source=transaction

Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.1016/j.cell.2020.02.052?utm_medium=email&utm_source=transaction

Joyner, Carter, Senefeld, Convalescent plasma antibody levels and the risk of death from Covid-19, N Engl J Med, doi:10.1056/NEJMoa2031893?utm_medium=email&utm_source=transaction

Levi, Thachil, Iba, Levy, Coagulation abnormalities and thrombosis in patients with COVID-19, Lancet Haematol, doi:10.1016/S2352-3026(20)30145-9?utm_medium=email&utm_source=transaction

Li, Zhang, Hu, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2020.10044?utm_medium=email&utm_source=transaction

Marovich, Mascola, Cohen, Monoclonal antibodies for prevention and treatment of COVID-19, JAMA, doi:10.1001/jama.2020.10245?utm_medium=email&utm_source=transaction

Pinto, Park, Beltramello, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature, doi:10.1038/s41586-020-2349-y?utm_medium=email&utm_source=transaction

Regeneron, None

Rogers, Shehadeh, Mylona, Convalescent plasma for patients with severe COVID-19: a matched cohort study, Clin Infect Dis, doi:10.1093/cid/ciaa1548?utm_medium=email&utm_source=transaction

Rosas, Bräu, Waters, Tocilizumab in hospitalized patients with COVID-19 pneumonia, MedRxiv, doi:10.1101/2020.08.27.20183442?utm_medium=email&utm_source=transaction

Shang, Zhao, Hu, Du, Cao, On the use of corticosteroids for 2019-nCoV pneumonia, Lancet, doi:10.1016/S0140-6736(20)30361-5?utm_medium=email&utm_source=transaction

Spinner, Gottlieb, Criner, Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. A randomized clinical trial, JAMA, doi:10.1001/jama.2020.16349?utm_medium=email&utm_source=transaction

Tang, Li, Wang, Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost, doi:10.1111/jth.14768?utm_medium=email&utm_source=transaction

Vabret, Britton, Gruber, Immunology of COVID-19: current state of the science, Immunity, doi:10.1016/j.immuni.2020.05.002?utm_medium=email&utm_source=transaction

Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2035002?utm_medium=email&utm_source=transaction

Zhou, Fu, Zheng, Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients, Natl Sci Rev, doi:10.1093/nsr/nwaa041?utm_medium=email&utm_source=transaction

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0